FDA approved more first-in-class drugs, gave more accelerated approvals in 2021
Regulatory NewsJeff Craven
Biologics/ biosimilars/ vaccinesHealth Authority meeting and communication strategyNorth AmericaPharmaceuticalsProduct LifecycleRegulatory Intelligence/Policy